Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

99.48EUR
11:35am EDT
Price Change (% chg)

€0.19 (+0.19%)
Prev Close
€99.29
Open
€99.90
Day's High
€99.96
Day's Low
€99.01
Volume
1,665,213
Avg. Vol
1,575,923
52-wk High
€106.80
52-wk Low
€81.82

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 0.92
Market Cap (Mil.): €82,107.65
Shares Outstanding (Mil.): 826.95
Dividend: 2.10
Yield (%): 2.12

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 23.79 35.65 36.07
EPS (TTM): 4.17 -- --
ROI: 8.61 18.91 18.18
ROE: 16.97 19.67 19.05
Search Stocks

UPDATE 1-Drug maker Orion's Q2 profit rises on Bayer, Takeda payments

* Result boosted by one-off payments from Bayer and Takeda

6:13am EDT

Drug maker Orion's Q2 profit rises on Bayer payments

HELSINKI, July 29 - Finnish drug maker Orion reported its second-quarter operating profit rose 41 percent from a year ago, boosted by upfront payments from Germany's Bayer.

5:11am EDT

French lawmakers back Roche cancer drug as cheap eye treatment

* EU shift to Avastin a threat to Novartis, Bayer profits

08 Jul 2014

China approves Bayer deal to buy Dihon, other deals

SHANGHAI, July 4 - The Chinese Ministry of Commerce's anti-monopoly bureau has approved German drugmaker Bayer AG's deal for traditional Chinese medicine (TCM) drugmaker Dihon Pharmaceutical Group Co, in a raft of deals approved on Friday.

04 Jul 2014

UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands

* Coppertone, Dr. Scholl's draw interest after $14 bln deal

01 Jul 2014

CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands

(Corrects fourth paragraph to read "portfolio acquired from Merck", not "portfolio acquired by Merck")

01 Jul 2014

German manufacturing grows in June at weakest rate in eight months: PMI

BERLIN, - German manufacturing grew at the slowest rate in eight months in June, a survey showed on Tuesday, adding to signs that the expansion in Europe's largest economy lost momentum in the second quarter.

01 Jul 2014

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

27 Jun 2014

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT, June 27 - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

27 Jun 2014

New Issue-Bayer prices a dual tranche deal

Underlying govt bond Over the 3.25 pct January 2020 DBR

25 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks